Bharat Biotech gets nod for phase 2/3 clinical trials of Covaxin on 2 to 18-year-olds

On Tuesday, the Subject Expert Committee on Covid-19 of the Central Drugs Standard Control Organization (CDSCO) deliberated upon Hyderabad-based Bharat Biotech's application seeking permission to conduct the clinical trials to evaluate the safety, reactogenicity and immunogenicity of Covaxin jabs among children.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3eECXsd
via IFTTT